| Title |
Harnessing the immune system for the treatment of breast cancer
|
|---|---|
| Published in |
Journal of Zhejiang University - Science B, January 2014
|
| DOI | 10.1631/jzus.b1300264 |
| Pubmed ID | |
| Authors |
Xinguo Jiang |
| Abstract |
Standard treatment options for breast cancer include surgery, chemotherapy, radiation, and targeted therapies, such as adjuvant hormonal therapy and monoclonal antibodies. Recently, the recognition that chronic inflammation in the tumor microenvironment promotes tumor growth and survival during different stages of breast cancer development has led to the development of novel immunotherapies. Several immunotherapeutic strategies have been studied both preclinically and clinically and already have been shown to enhance the efficacy of conventional treatment modalities. Therefore, therapies targeting the immune system may represent a promising next-generation approach for the treatment of breast cancers. This review will discuss recent findings that elucidate the roles of suppressive immune cells and proinflammatory cytokines and chemokines in the tumor-promoting microenvironment, and the most current immunotherapeutic strategies in breast cancer. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| Central African Republic | 1 | 20% |
| Canada | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 82 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 19% |
| Student > Bachelor | 13 | 15% |
| Student > Doctoral Student | 9 | 11% |
| Student > Master | 9 | 11% |
| Student > Postgraduate | 6 | 7% |
| Other | 13 | 15% |
| Unknown | 18 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 20 | 24% |
| Medicine and Dentistry | 18 | 21% |
| Biochemistry, Genetics and Molecular Biology | 15 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Immunology and Microbiology | 3 | 4% |
| Other | 3 | 4% |
| Unknown | 21 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2016.
All research outputs
#14,536,007
of 25,374,647 outputs
Outputs from Journal of Zhejiang University - Science B
#336
of 704 outputs
Outputs of similar age
#169,747
of 319,280 outputs
Outputs of similar age from Journal of Zhejiang University - Science B
#8
of 12 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 704 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,280 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.